-
1 Comment
Jinyu Bio-technology Co., Ltd is currently in a long term downtrend where the price is trading 17.0% below its 200 day moving average.
From a valuation standpoint, the stock is 60.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
Jinyu Bio-technology Co., Ltd's total revenue rose by 43.6% to $483M since the same quarter in the previous year.
Its net income has increased by 44.4% to $113M since the same quarter in the previous year.
Finally, its free cash flow grew by 1691.8% to $218M since the same quarter in the previous year.
Based on the above factors, Jinyu Bio-technology Co., Ltd gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Exchange | SHG |
| CurrencyCode | CNY |
| ISIN | CNE000000Y37 |
| Sector | Healthcare |
| Dividend Yield | 0.2% |
|---|---|
| Beta | 0.77 |
| Market Cap | 17B |
| PE Ratio | 153.4 |
| Target Price | 7.18 |
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines. It also provides ruminant vaccines, such as foot and mouth disease trivalent, bovine pasteurella multocida, combined bovine viral diarrhea disease and infectious bovine rhinotracheitis, brucella gene deletion, goat pox, brucellosi, brucellosis, foot and mouth disease bivalent and type O, clostridium chauvoei, lumpy skin disease, combined ovine infectious necrotic hepatitis and braxy, and caprine infectious pleuropneumonia, as well as combined ovine braxy, struck, lamb dysentery, enterotoxaemia, and black disease and clostridium botulinum toxonosis vaccines. In addition, the company offers avian vaccines; rabies vaccines; and PCR and Elisa diagnostic kits. Further, it is involved in manufacturing and sales of veterinary chemical preparations, chemical reagents and auxiliary agents, biological drug preparations, and advanced medical equipment and instruments; biotechnology development, transfer, and consulting services; import and export of goods and technology; and provision of property management services. The company was founded in 1992 and is headquartered in Hohhot, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600201.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
